expanding the potential
of immunotherapy
One pathway,
many possibilities
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology.
scientific
founders.
Chief Executive Officer
Chief Business Officer
Chief Medical Officer
news.
NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX267, a Novel Therapeutic Targeting KIR3DL3 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs
What’s NEXT for you?
Clinical Trial Manager / Senior Clinical Trial Manager
© nextpoint 2023. All Rights Reserved.
LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142
info@nextpointtx.com | 508-204-1115
First-in-class monoclonal antibody targeting KIR3DL3, the inhibitory receptor for HHLA2, designed to reverse immune suppression in the tumor microenvironment
The study will assess safety, tolerability and inform dosing strategy
Cambridge, MA – August 17, 2023 – NextPoint Therapeutics, a clinical-stage biotechnology company developing precision immuno-oncology therapeutics targeting the novel HHLA2 pathway, announced today that the first patient has been dosed with NPX267 in a Phase 1 first-in-human clinical trial for the treatment of patients with solid tumors known to express HHLA2, a tumor antigen strongly upregulated in many human tumors independently of PD-L1.
The Phase 1a/1b open-label, multi-center study (NCT05958199) consists of a dose escalation and an expansion stage to evaluate the tolerability, pharmacokinetics, immunogenicity and biomarker strategy of NPX267 in patients with metastatic solid tumors including epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) and other indications.
Killer cell immunoglobulin-like receptor 3DL3 (KIR3DL3) is expressed on effector T cells and natural killer (NK) cells in the tumor microenvironment and is an inhibitory receptor for the tumor antigen HHLA2, expressed on a range of solid tumors. Binding of KIR3DL3 to HHLA2 is believed to allow tumors to cloak themselves and hide from immune cells.
“Many cancers hijack the HHLA2 pathway to evade the immune system, whose signaling mechanisms were independently co-discovered by NextPoint’s scientific co-founders, Dr. XingXing Zang and Dr. Gordon Freeman,” said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. “Because HHLA2 is expressed independently of PD-L1 and is often highly expressed in PD-L1-negative cancers, targeting the HHLA2-KIR3DL3 interaction is a promising new approach for patients with cancer.”
“We are excited to launch the clinical evaluation of NPX267, our lead therapeutic program targeting the HHLA2 pathway,” said Leena Gandhi, MD, PhD, Chief Medical Officer of NextPoint Therapeutics. “This study will provide important data on the therapeutic activity of NPX267 as well as the mechanism of HHLA2-mediated immunosuppression via KIR3DL3 and inform our clinical strategy for developing precision immunotherapeutic treatments for patients.”
About NPX267
NPX267 is a first-in-class monoclonal antibody targeting KIR3DL3, the inhibitory receptor for the HHLA2 pathway (B7-H7), and is designed to prevent immune escape in solid tumors. By blocking the binding of KIR3DL3 on exhausted T and NK cells to HHLA2 expressed on tumor cells, NPX267 may be able to reactivate tumor antigen-primed immune cells in HHLA2-expressing solid tumors. Preventing KIR3DL3-mediated immune suppression may enhance anti-tumor immune responses for patients with HHLA2-positive cancers – a tumor antigen expressed independently of PD-L1. To learn more, visit www.clinicaltrials.gov (NCT05958199).
About NextPoint Therapeutics
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To learn more, visit nextpointtx.com.
Contacts
Media Contact
Chelsea Rule
MacDougall Advisors
1(781)235-3060
crule@macdougall.bio
Cambridge, MA – March 21, 2023 – NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that Axel Hoos, MD, PhD, has joined the NextPoint Board of Directors. Dr. Hoos currently serves as the Chief Executive Officer of Scorpion Therapeutics and brings a wealth of business, entrepreneurial and biopharmaceutical research and development expertise to the role.
“Dr. Hoos is a recognized pioneer in immuno-oncology and has shaped the checkpoint therapeutic landscape through his work on a new development paradigm for IO medicines and the development of the anti-CTLA-4 antibody ipilimumab, the first FDA-approved checkpoint immunotherapy,” commented Detlev Biniszkiewicz, PhD, CEO of NextPoint Therapeutics. “Our team will benefit greatly from Dr. Hoos’ expertise and perspective as we advance our novel immuno-oncology programs targeting the HHLA2 pathway to the clinic.”
“Immuno-oncology has become a critical component in our treatment armamentarium for cancer patients, and scientists are seeking the next breakthrough medicine to further expand its reach. I am looking forward to working with the executive team and fellow Board members to help NextPoint realize its promise to deliver the next IO breakthrough,” said Dr. Hoos. “NextPoint’s work on the HHLA2 pathway has the potential to expand the reach of precision immuno-oncology to a range of patients who do not benefit from currently available therapies.”
Prior to becoming CEO of Scorpion, Dr. Hoos served as Senior Vice President, R&D Governance Chair, and Therapeutic Area Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). In that role, Dr. Hoos built the Oncology business across all therapeutic modalities in the focus areas of immuno-oncology, synthetic lethality, tumor cell targeting, epigenetics, and cell & gene therapy. He is a member of the Board of Trustees at the Sabin Vaccine Institute, Director on the Board of TCR2, and member of the Scientific Advisory Board and Co-Director of the Cancer Immunotherapy Consortium at the Cancer Research Institute. Dr. Hoos received his MD in Medicine from Heidelberg University, and his PhD in Molecular Oncology from the German Cancer Research Center. He trained in general surgery at the Technical University of Munich and as a fellow in cancer research at Memorial Sloan-Kettering Cancer Center.
About NextPoint Therapeutics
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To learn more, visit nextpointtx.com.
Media Contact
Chelsea Rule
MacDougall Advisors
crule@macdougall.bio
Cambridge, MA – February 21, 2023 – NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).
As CMO, Dr. Gandhi will oversee the clinical development of NextPoint’s precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer.
“Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth,” said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. “We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis.”
“I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients,” commented Dr. Gandhi. “NextPoint’s outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.”
Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. In Dr. Gandhi’s next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub.
About NextPoint Therapeutics
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To learn more, visit nextpointtx.com.
Contacts
Media Contact
Lauren Arnold
MacDougall Advisors
1(617)694-5387
larnold@macdougall.bio
Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells
Cambridge, MA / Leverkusen, Germany – January 10, 2023 – NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.
Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institute’s Binney Street Capital and NextPoint founder Gordon Freeman, PhD. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors.
NextPoint’s programs aim to deliver monotherapies for cancer patients without viable treatment options. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. NextPoint’s approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion.
NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Drs. Freeman’s and Zang’s independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4.
“NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression,” said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. “The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments.”
Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, “Leaps by Bayer was founded to help solve ten of the world’s biggest challenges in health and agriculture, including preventing and curing cancer. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.”
About NextPoint Therapeutics
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To learn more, visit nextpointtx.com.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.
About Leaps by Bayer
Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of today’s biggest challenges in health and agriculture. The investment portfolio includes more than 50 companies. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. For more information, go to leaps.bayer.com.
About Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofi’s business footprint, and digital health solutions. Find out more: www.sanofiventures.com
Contacts
Media Contact
Lauren Arnold
MacDougall Advisors
1(617)694-5387
larnold@macdougall.bio
Kira Peikoff
Leaps by Bayer
1(973)791-3348
kira.peikoff@bayer.com
Summary
NextPoint Therapeutics, Inc. is an exciting development-stage Boston-area startup company working at the frontier of immuno-oncology on a novel checkpoint axis with multiple programs entering the clinic. We are currently looking to add a Clinical Trial Manager/Senior Clinical Trial Manager to our fast moving, roll-up your sleeves team environment. Reporting to the VP, Clinical Development Operations, the successful candidate will be responsible for all aspects of clinical trial management for two global phase 1 oncology studies.
What are we offering to you?
This is an outstanding opportunity to join a well-funded startup company early in its trajectory. You will be a vital part of a team striving transform cancer treatment and deliver patient cures. You will have a direct and significant impact on how we operationalize our clinical studies. You will also help to shape the NextPoint culture and be a part of a passionate, transparent, and collaborative work environment.
We are looking for someone who can bring significant capability to deliver on the operational needs of the role, while bringing a thoughtful perspective, drive for results, collaborative approach, and the ability to work with, influence, and communicate with a variety of stakeholders.
Responsibilities
Your Background:
Interested in finding out more?
Please send your resume and cover letter to HR@nextpointtx.com.
Summary
NextPoint Therapeutics is an exciting development-stage Boston-area startup company working at the frontier of immuno-oncology on a novel checkpoint axis with multiple programs entering the clinic. We are currently looking for a Director/Senior Director, Clinical Pharmacology to our fast moving, roll-up your sleeves team environment. Reporting to the Chief Medical Officer, the Director/Senior Director, Clinical Pharmacology will be responsible for all aspects of the clinical pharmacology strategy including early clinical development (phase I/II studies). We are a nimble, innovative, and driven company and looking for an experienced individual to join our growing team.
Responsibilities
Experience and Qualifications
To apply, please reach out to: Randy Rongione, rrongione@kleinhersh.com.
Summary
NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs.
Responsibilities
Experience and Qualifications
Medical Requirements
COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations.
Interested in finding out more?
Please send your resume and cover letter to HR@nextpointtx.com.
NextPoint Therapeutics, Inc. (“NextPoint,” “we,” “us” or “our”) has created a website at https://www.nextpointtx.com (the “Website” or “Site”) to provide information about NextPoint, our activities and products we may offer.
To assist you in using the Website, we have created (i) these Terms of Use (the “Terms”), and (ii) a Privacy Notice. Our Privacy Notice explains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. Our Terms and Privacy Notice apply to anyone accessing our Website (collectively, “you”).
PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT.
450 Kendall Street
Cambridge, MA 02142
24. Effective Date. The effective date of these Terms is May 18, 2022.
25. Copyright and Legal Notice. Copyright ©2022 NextPoint Therapeutics, Inc. All Rights Reserved.
LAST UPDATED: May 18, 2022
This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (“NextPoint”) collects, uses, and shares Personal Data that you submit to us and that we collect through our website https://www.nextpointtx.com (the “Site”). The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer.
INFORMATION WE COLLECT
For purposes of this Privacy Notice, “Personal Data” means any information relating to an identified or identifiable natural person. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site.
We may collect Personal Data as follows:
You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you.
USE OF COOKIES AND SIMILAR TECHNOLOGIES
The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. We also use cookies and similar technologies for purposes of marketing and advertising.
A “cookie” is a small text file that a web server stores in browser software. A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie). The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. Cookies can remember login information, preferences, and similar information.
Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as “Flash” cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data.
We may also use web beacons or “pixels,” and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data.
If you want to block the use and saving of cookies from the Site on to the computers’ hard drive, you should take the necessary steps within your web browser’s settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. For information on how to disable cookies, refer to your browser’s documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies).
Our Site may use the following technologies to implement cookies and pixels:
If you do not wish to receive any interest-based advertising, you can deactivate Google’s use of cookies for these purposes by going to https://www.google.com/settings/ads. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiative’s deactivation page (link: https://optout.networkadvertising.org/?c=1).
Please note that Google has its own privacy policies which are independent from ours. We do not accept any responsibility or liability for these policies and procedures. Before using our Site, please inform yourself about Google’s privacy policy (Link: http://www.google.com/privacy.html).
HOW WE USE THE INFORMATION WE COLLECT
We may use Personal Data for a variety of different purposes as set out in further detail below. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below.
In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data:
HOW WE MAY DISCLOSE INFORMATION
We may disclose Personal Data as described in this Privacy Notice, including:
DE-IDENTIFIED OR ANONYMOUS DATA
We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice.
DO-NOT-TRACK
Do-Not-Track is a public-private initiative that has developed a “flag” or signal that an Internet user may activate in the user’s browser software to notify websites that the user does not wish to be “tracked” by third-parties as defined by the initiative. The online community has not agreed on what actions, if any, should be taken by the websites that receive the “do not track” signal, and therefore Do-Not-Track is not yet standardized. Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser.
INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE
We do not knowingly collect information from minors under the age of 13 years without parental consent. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us at info@nextpointtx.com. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law.
LINKS TO OTHER SITES
Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively “Third-Party Sites”). We provide these links merely for your convenience. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. Our Privacy Notice does not apply to Third-Party Sites. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact.
CALIFORNIA RESIDENTS
If you are a resident of California and using our Site, the following information applies to you. For purposes of this section, “Personal Information” means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (“CCPA”).
We may collect Person Information from you in a variety of ways:
Category of Personal Information | Categories of Sources | Purpose of Collecting/Sharing | Categories of Third Parties to Whom We Disclose Personal Information |
---|---|---|---|
Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers | You, your computer and mobile devices when you access our Site | To allow you access to our Site and to provide you with services, such as responding to questions you may have | Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. |
Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education | N/A | We do not generally collect this information | N/A |
Commercial information, such a Services provided, your interaction with our Site and Services | You | To allow you access to our Services, to provide you with Services, to respond to questions you may have | Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. |
Biometric Information | N/A | We do not generally collect this information | N/A |
Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. | Your computer and mobile devices when you visit our Site. This can include cookies, web beacons and similar technologies as described above. | To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations | Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. |
Geolocation Data such as physical location information that may be provided by the device you are using | Your computer and mobile devices when you access our Site. | To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. | Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. |
Audio, electronic, visual, thermal, olfactory or similar information | N/A | We generally do not collect this type of information | N/A |
Inferences drawn from other Personal Information | You | To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations | Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. |
Exercising your Rights under CCPA
If you wish to exercise your rights under California law, please see the “Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA” section below for information on how to contact us to exercise your rights.
NextPoint does not sell your Personal Information.
In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights.
Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information.
You may only make a verifiable consumer request for access or data portability twice within a 12-month period. The verifiable consumer request must:
California Shine the Light Law:
California Civil Code Section 1798.83, known as the “Shine the Light” law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. We will never disclose your PII to third parties for direct marketing purposes without your authorization. However, if you would like to make a request for information under the Shine The Light law, please contact us at the “Contact Us” section below.
Requests may be made only once a year and are free of charge.
RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA)
Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Where we are processing your Personal Data, subject to applicable law, you also have the right to:
To exercise your rights, you may contact us as at info@nextpointtx.com. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Furthermore, where permissible, we may charge for this service. We will respond to reasonable requests as soon as practicable and as required by law. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement.
WITHDRAWING YOUR CONSENT
In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims.
Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us at info@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information.
If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. Alternatively, you may contact us at info@nextpointtx.com to opt-out of direct marketing. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site.
Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site.
TRANSFER OF DATA
Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. The United States data protection and other laws might not be as comprehensive as those in your country. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States.
DATA RETENTION
We will retain your Personal Data as may be required or permitted by applicable law. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements.
SECURITY
We use technical and organizational security measures designed to secure and protect Personal Data. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data.
UPDATES TO THIS PRIVACY NOTICE
We may update this Privacy Notice from time to time. The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. We encourage you to review this Privacy Notice often to stay informed of how we may process your information.
CONTACT US
For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail at info@nextpointtx.com or by mail at the following address:
NextPoint Therapeutics, Inc.
450 Kendall Street
Cambridge, MA 02142